Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer
https://doi.org/10.17650/1726-9776-2016-12-3-109-110
Abstract
Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer.
About the Authors
B. Ya. AlekseevRussian Federation
V. B. Matveev
Russian Federation
I. G. Rusakov
Russian Federation
M. I. Volkova
Russian Federation
O. B. Karjakin
Russian Federation
L. V. Bolotina
Russian Federation
G. P. Kolesnikov
Russian Federation
E. I. Kopylcov
Russian Federation
B. Sh. Kamolov
Russian Federation
K. M. Nyushkov
Russian Federation
V. A. Atduev
Russian Federation
P. A. Karnauch
Russian Federation
R. V. Smirnov
Russian Federation
O. G. Tonacheva
Russian Federation
D. V. Tevs
Russian Federation
A. A. Izmailov
Russian Federation
A. V. Govorov
Russian Federation
R. A. Gafanov
Russian Federation
S. V. Mishugin
Russian Federation
A. O. Karyakin
Russian Federation
References
1. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016.
2. Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015.
3. Ryan C.J., Tindall D.J. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29(27):3651–8.
4. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92.
5. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–91.
6. Beer T.M., Armstrong A.J., Rathkopf D.E. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.
7. Yap T.A., Zivi A., Omlin A., de Bono J.S. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8(10): 597–610.
8. Beltran H., Beer T.M., Carducci M.A. et al. New therapies for castrationresistant prostate cancer: efficacy and safety. Eur Urol 2011;60(2): 279–90.
Review
For citations:
Alekseev B.Ya., Matveev V.B., Rusakov I.G., Volkova M.I., Karjakin O.B., Bolotina L.V., Kolesnikov G.P., Kopylcov E.I., Kamolov B.Sh., Nyushkov K.M., Atduev V.A., Karnauch P.A., Smirnov R.V., Tonacheva O.G., Tevs D.V., Izmailov A.A., Govorov A.V., Gafanov R.A., Mishugin S.V., Karyakin A.O. Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. Cancer Urology. 2016;12(3):109-110. (In Russ.) https://doi.org/10.17650/1726-9776-2016-12-3-109-110
Views:
1069
Email this article 